Luca Gattinoni Curriculum Vitae 2013 - Center for Cancer Research ...

More documents

Recommendations

Info

24. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP. Adoptively transferred effector cells derived from naive rather than central memory CD8 + T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009, 106:17469–17474 25. Klebanoff CA, Yu Z, Hwang L, Palmer DC, Gattinoni L, Restifo NP. Programming tumor-reactive effector memory CD8 + T cells in vitro obviates the requirement for in vivo vaccination. Blood 2009, 114:1776–1783 26. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Church L, Paulos CM, Muranski P, Restifo NP. Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells. Nature Med 2009, 15:808–813 27. Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008, 112:4746–4754 28. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann K, Feigenbaum L, Chan CC, Restifo NP. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362–373 29. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ Jr, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA 2008, 105:8061–8066 30. Hinrichs CS, Spolsky R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8 + T cells for adoptive immunotherapy. Blood 2008 , 111:5326–5333 31. Abad JD, Wrzesinski C, Overwijk WW, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. J Immunother 2008, 31:1–6 32. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony, PA, Gattinoni L , Rosenberg SA, Restifo, NP. Toll-like receptors in Tumor Immunotherapy. Clin Cancer Res 2007, 13:5280–5289 33. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo, NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via Toll-Like Receptor 4. J Clin Invest 2007, 117:2197–2204 34. Lionello L, Mangia P, Gattinoni L, Pende D, Cipponi A, Sensi M, Rigatti P, Traversari C. CD8 + T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. Cancer Immunol Immunother 2007, 56:1065–1076 35. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L , Restifo NP, Rosenberg SA, Morgan RA. Extra-thymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res, 2007, 67:2425–242932. 36. Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA and Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 + T cells. J Clin Invest 2007, 117: 492– 501 37. Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP. CTLA-4 dysregulation of self/tumor-reactive CD8 + T cell function is CD4 + T cell-dependent. Blood 2006, 108:3818– 3823 38. Klebanoff CA*, Gattinoni L*, Restifo NP. CD8 + T cell memory in tumor immunology and immunotherapy. Immunol rev 2006, 211:214–224 * equally contributed 39. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8 + T cells for effective immunotherapy. Curr Opin Immunol, 2006, 18:363–370 40. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nature Rev Immunol 2006, 6:383–393 41. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Mol Ther 2006, 13:151–159 42. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. J Exp Med 2005, 202:907–912 43. Klebanoff CA*, Gattinoni L*, Torabi-Parizi P, Kerstann K, Cardones AR, Finkselstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005, 102:9571–9576 * equally contributed 44. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells. J Clin Invest. 2005, 115:1616–1626
45. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre, S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005, 23: 2155–2161 46. Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC Restifo NP Vaccine-stimulated, Adoptively Transferred CD8 + T Cells Traffic Indiscriminately And Ubiquitously While Mediating Specific Tumor Destruction. J Immunol 2004, 173:7209–7216 47. Finkelstein SE, Heimann DM, Klebanoff AC, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR , Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP: Bedside to bench and back again: How animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 2004, 76:333–337 48. Melloni G, Ferreri AJM, Russo V, Gattinoni L, Arrigoni L, Ceresoli GL, Zanini P, Traversari C. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 2004, 12:145–151 49. Klebanoff AC, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP: IL-15 enhances the in vivo anti-tumor activity of tumor-reactive CD8 + T cells. Proc Natl Acad Sci USA 2004, 101: 1969–1974 50. Del Vecchio M, Gattinoni L, Lozza L, Bajetta E. Regionally Advanced Nasal Cavity Melanoma. J Clin Oncol 2004, 22: 745–746 51. Gattinoni L, Alù M, Ferrari L, Nova P, Del Vecchio M, Procopio G, Laudani A, Agostara B, Bajetta E. Renal cancer treatment: a review of the literature. Tumori 2003, 89: 476–484 52. Ferrari L, Bajetta E, Martinetti A, Celio L, Longarini R, La Torre I, Buzzoni R, Gattinoni L, Seregni E, Bombardieri E. Could Exemestane affect on Insuline-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol 2003, 22: 1081–1089 53. Ferrari L, Martinetti A, Zilembo N, Pozzi P, Buzzoni R, La Torre I, Gattinoni L, Catena L, Vitali M, Celio L, Seregni E, Bombardieri E, Bajetta E. Short-term effects of Anastrozole treatment on Insuline-Like Growth Factor System in postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol 2002, 80: 411–418 54. Fleischhauer K, Gattinoni L, Lietti G, Zino E, Bordignon C, Traversari C. Identification of Tumor Antigen Specific Cytotoxic T Lymphocytes cross-recognizing allogenic major histocompatibility class I molecules. Tissue Antigens 2000, 56: 19–29 55. Fleischhauer K, Gattinoni L, Dalerba P, Lauvau G, Zanaria E, Dabovic B, van Endert P, Bordignon C,Traversari C. The DAM-Gene Family encodes a New Group of Tumor-specific Antigens recognised by Human Leukocyte Antigen A2- Restricted Cytotoxic T Lymphocytes. Cancer Res 1998, 58: 2969–2972 Invited Lectures 1. T memory stem cells sustain the long-term maintenance of T cell memory. Keystone Symposia: Emerging Topics in Immune System Plasticity, Santa Fe, NM, US, January 15-20, 2013 2. Paths to stemness: building the ultimate antitumour T cell. JNI Oncology Lectures, Erasmus MC, Rotterdam, The Netherlands, October 24, 2012 3. A human memory T cell subset with stem cell-like properties. CHI symposium: The human immune system after perturbation and in disease, Bethesda, MD, US, October 9, 2012 4. Fighting fire with fire: Eradicating tumors with stem cell-like T cells. Immunology and Inflammation in Cancer. Wilson S. Stone Memorial Award Lecture. MD Anderson Cancer Center, Houston, TX, US, September 21-22, 2012 5. Programming and reprogramming T cell fate for therapeutic use. NCMLS seminar, Nijmegen, The Netherlands, June 11, 2012 6. Fighting fire with fire: Eradicating tumors with stem cell-like T cells. Dutch Tumor Immunology Meeting, Keynote Lecture, Breukelen, The Netherlands, June 7-8, 2012 7. Programming and reprogramming T cell fate for therapeutic use. Experimental Transplantation Immunology Branch seminar, Bethesda, MD, US, March 21, 2012 8. Identification of self-renewing, multipotent CD8 + memory stem cells in mice and humans. Summit on Cell Therapy for Cancer, Bethesda, MD, US, November 1-2, 2011 9. The self-renewing, multipotent CD8 + memory stem cells. BB&B lecture series FOCIS/CHI, NIH, Bethesda, MD, US, October 19, 2011 10. The self-renewing, multipotent CD8 + memory stem cells. 44th SLB (Society for Leukocyte Biology) Annual Meeting, Kansas City, MO, September 22-24, 2011 11. An early human memory T cell subset with stem cell-like properties. Keystone Symposia: Immunologic Memory, Persisting Microbes and Chronic Disease, Banff, Alberta, Canada, February 6-11, 2011 12. Adoptive immunotherapy in immune-depleted melanoma patients. 5 th Meeting on Combined Biotherapy of Cancer of the Program 2 Alleanza contro il cancro, Milan, Italy, April 9 -10, 2010 13. Basic principles guiding the development of new adoptive immunotherapies. University of Lausanne, Epalinges, Switzerland, December 16, 2009 14. Basic principles guiding the development of new adoptive immunotherapies. EXTERNAL SEMMinars, European School of Molecular Medicine, Milan, Italy , December 14, 2009 15. Activation of Wnt Signaling with Inhibitors of Gsk-3 Promotes the Generation of highly effective CD8 + Memory Stem Cells for immunotherapy. WNT 2009 Meeting, Washington, DC, US, June 11-14, 2009
Page 1 and 2: Business Address National Cancer In
Page 3: Peer reviewed Publications 1. Dudda

Luca Gattinoni Curriculum Vitae 2013 - Center for Cancer Research ...

Create successful ePaper yourself

Delete template?

Save as template?